Received Apr 16, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No adverse effects reported.; he received his second GARDASIL 9 vaccine at 6 months instead of the recommended 2 month interval for his age; This spontaneous report was received from the patient referring to himself as 31-year-old male patient. The patient's pertinent medical history, previous drug reactions or allergies and concomitant medications were not provided. On 03-Sep-2025, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) dose number 1 as prophylaxis then, on 26-Mar-2026, the second dose of it (doses, route of administration, lot numbers and expiration dates were not provided). The consumer reports that he received his second Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) vaccine at 6 months instead of the recommended 2-month interval for his age (Inappropriate schedule of product administration). No adverse effects reported. No other information provided. Lot # is being requested and will be submitted if received